VIVA 23: SAVER: Gender Subgroup Analysis

Published: 03 Nov 2023

  • Views:

    Views Icon 82
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

VIVA 23 - We are joined virtually by Dr Marianne Brodmann (Medical University of Graz, AT) to discuss the findings of the Stellarex Vascular E-Registry (SAVER) study of the Gender Subgroup analysis.

The SAVER subgroup analysis was a real-world registry with over 1800 Rutherford category 2-6 patients included. The results suggested that the low-dose paclitaxel-coated Stellarex Balloon behaved efficiently across gender subgroups, as well as patients with diabetes. 

Interview Questions:

  1. What was the reasoning behind this study?
  2. What was the patient population and study design?
  3. What are the late-breaking findings?
  4. What are your take-home messages?
  5. What further study is needed?

Recorded remotely from Graz, 2023.

Editor: Jordan Rance
Video Specialist: Dan Brent


You must be to comment. If you are not registered, you can register here.